Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

50 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Regional Nodal Irradiation in Early-Stage Breast Cancer.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators. Whelan TJ, et al. Among authors: Craighead P. N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340. N Engl J Med. 2015. PMID: 26200977 Free PMC article. Clinical Trial.
The rates of disease-free survival were 82.0% in the nodal-irradiation group and 77.0% in the control group (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Patients in the nodal-irradiation group had higher rates of grade 2 or greater acute pneumonitis (1.2% vs. 0.2%, P=0.01) and lymphedema (8.4% vs. 4.5%, P=0.001). ...
The rates of disease-free survival were 82.0% in the nodal-irradiation group and 77.0% in the control group (hazard ratio, 0.76; 95% CI, 0.6 …
Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens.
Britten RA, Perdue S, Opoku J, Craighead P. Britten RA, et al. Among authors: Craighead P. Radiother Oncol. 1998 Sep;48(3):329-34. doi: 10.1016/s0167-8140(98)00084-x. Radiother Oncol. 1998. PMID: 9925253
RESULTS: Raf-1 kinase activity was inversely correlated (P = 0.001) with SF2 values in the 12 cervical tumor clones studied. Paclitaxel was preferentially cytotoxic to radioresistant tumor clones, with the level of paclitaxel-induced cytotoxicity being significantly (P = 0.0016) influenced by Raf-1 kinase activity levels. ...
RESULTS: Raf-1 kinase activity was inversely correlated (P = 0.001) with SF2 values in the 12 cervical tumor clones studied. Paclitax …
High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study.
Stewart DA, Paterson AH, Ruether JD, Russell J, Craighead P, Smylie M, Mackey J. Stewart DA, et al. Among authors: Craighead P. Ann Oncol. 2005 Sep;16(9):1463-8. doi: 10.1093/annonc/mdi268. Epub 2005 Jun 9. Ann Oncol. 2005. PMID: 15946980
One-Year Cosmesis and Fibrosis From ACCEL: Accelerated Partial Breast Irradiation (APBI) Using 27 Gy in 5 Daily Fractions.
Grendarova P, Roumeliotis M, Quirk S, Lesiuk M, Craighead P, Liu HW, Pinilla J, Wilson J, Bignell K, Phan T, Olivotto IA. Grendarova P, et al. Among authors: Craighead P. Pract Radiat Oncol. 2019 Sep-Oct;9(5):e457-e464. doi: 10.1016/j.prro.2019.04.002. Epub 2019 Apr 9. Pract Radiat Oncol. 2019. PMID: 30978468 Clinical Trial.
Quality indicators for ductal carcinoma in situ (DCIS) of the breast: development using a multidisciplinary delphi process and its use in monitoring population-based treatment.
Chin-Lenn L, Craighead P, Bryant HE, Mack L, Temple W, Ghali W, Quan ML. Chin-Lenn L, et al. Among authors: Craighead P. J Surg Oncol. 2013 Nov;108(6):348-51. doi: 10.1002/jso.23401. Epub 2013 Aug 22. J Surg Oncol. 2013. PMID: 24038038
Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.
DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ. DiSilvestro PA, et al. Among authors: Craighead PS. J Clin Oncol. 2014 Feb 10;32(5):458-64. doi: 10.1200/JCO.2013.51.4265. Epub 2014 Jan 6. J Clin Oncol. 2014. PMID: 24395863 Free PMC article. Clinical Trial.
Three-year PFS for the TPZ/CIS/RT and CIS/RT arms were 63.0% and 64.4%, respectively (log-rank P = .7869). Three-year OS for the TPZ/CIS/RT and CIS/RT arms were 70.5% and 70.6%, respectively (log-rank P = .8333). ...
Three-year PFS for the TPZ/CIS/RT and CIS/RT arms were 63.0% and 64.4%, respectively (log-rank P = .7869). Three-year OS for the TPZ/ …
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB, Wu JS, Craighead PS, Phan T, Köbel M, Lees-Miller SP, Ghatage P, Magliocco AM, Doll CM. McIntyre JB, et al. Among authors: Craighead PS. Gynecol Oncol. 2013 Mar;128(3):409-14. doi: 10.1016/j.ygyno.2012.12.019. Epub 2012 Dec 22. Gynecol Oncol. 2013. PMID: 23266353
PIK3CA mutation status was strongly associated with overall survival (OS) in FIGO stage IB/II patients, unadjusted HR 6.0 (95% CI 2.1-17.5), p=0.0002, but not stage III/IVA patients, unadjusted HR 1.0 (95% CI 0.32-3.1), p=0.98. ...
PIK3CA mutation status was strongly associated with overall survival (OS) in FIGO stage IB/II patients, unadjusted HR 6.0 (95% CI 2.1-17.5), …
The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM, Aquino-Parsons C, Pintilie M, Klimowicz AC, Petrillo SK, Milosevic M, Craighead PS, Clarke B, Lees-Miller SP, Fyles AW, Magliocco AM. Doll CM, et al. Among authors: Craighead PS. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):721-7. doi: 10.1016/j.ijrobp.2012.06.021. Epub 2012 Jul 24. Int J Radiat Oncol Biol Phys. 2013. PMID: 22836058 Clinical Trial.
OS was associated with tumor size (HR 1.16, P=.018), pretreatment hemoglobin status (HR 2.33, P=.00027), and FIGO stage. In addition, tumoral ERCC1 status (nuclear to cytoplasmic ratio) was associated with PFS (HR 2.33 [1.05-5.18], P=.038) and OS (HR 3.13 [1.27-7.71], P=.013). ERCC1 status was not significant on multivariate analysis when the model was adjusted for the clinical factors: for PFS (HR 1.49 [0.61-3.6], P=.38); for OS (HR 2.42 [0.94-6.24] P=.067). ...
OS was associated with tumor size (HR 1.16, P=.018), pretreatment hemoglobin status (HR 2.33, P=.00027), and FIGO stage. In ad …
50 results
Jump to page
Feedback